close

Agreements

Date: 2016-03-07

Type of information: Opening of new premises

Compound: Asia Pacific headquarters in Singapore

Company: Ferring Pharmaceuticals (Switzerland)

Therapeutic area: Gastrointestinal diseases - Digestive diseases - Women health - Fertility - Endocrinological diseases - Hormonal diseases

Type agreement:

opening of new premises

Action mechanism:

Disease:

Details:

* On March 7, 2016, Ferring Pharmaceuticals announced the inauguration of their new Asia Pacific headquarters at Capital Tower in Singapore. The new headquarters will have strategic oversight and executive management responsibilities over the company’s regional entities and activities in Asia Pacific – a region identified for fast growth and future development and investment by Ferring Pharmaceuticals. The new Ferring Asia-Pacific Regional Headquarters focuses on supply chain planning and coordination to support the growth of emerging markets in Asia with central functions.

The new Ferring Asia-Pacific Regional Headquarters will facilitate collaboration across various operational disciplines and will see functions such as supply chain planning and coordination, intellectual property management, IT, business development and planning, sales and marketing, regulatory and medical affairs coming together to support the Asia Pacific countries where Ferring operates. The Company aims to establish an agile supply chain with local packaging activities that will support the growth of its Asia Pacific countries. Singapore’s strategic location allows Ferring to respond faster to customers’ needs as customer service and support can be provided in the same time zone now, potentially reducing supply lead time by up to 2 months.

Ferring Asia Pacific will have opportunities for professionals operational in the above fields and will open with around 45 employees. Ferring expects that significantly more than ¾ of these employees will come directly from Singapore. Ferring Asia-Pacific Regional Headquarters commits S$10mil over five years for R&D in several therapeutic areas, including female healthcare

 

Financial terms:

Latest news:

Is general: Yes